Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Overview

This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA). At least 250 subjects will participate. The study is going to be conducted in approximately 50 sites in the United States and Canada.

Full Title of Study: “A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 2015

Detailed Description

This research is being done to compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure over the 16-week treatment period. Vehicle looks the same as HP802-247 but contains no cells. Target wound status is evaluated at each study visit (closed, open, reopened). At wound closure or completion of treatment all subject will enter an observational safety followed up period which ends at one year after initial exposure to test article.

Interventions

  • Biological: HP802-247
    • HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
  • Biological: Vehicle

Arms, Groups and Cohorts

  • Experimental: HP802-247
    • HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
  • Placebo Comparator: Vehicle
    • Vehicle Control(fibrinogen solution & thrombin solution without cells)

Clinical Trial Outcome Measures

Primary Measures

  • Wound Closure
    • Time Frame: 16 Weeks
    • Compare HP802-247 plus compression therapy against Vehicle plus compression therapy for proportion of subjects with complete wound closure over the 16-week treatment period from baseline.

Secondary Measures

  • Time in Days to Closure
    • Time Frame: 16 Weeks
    • Compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure, based on time in days to closure over the 16-week treatment period from baseline.

Participating in This Clinical Trial

Inclusion Criteria

  • Provide informed consent. – Age ≥ 18 years and of either sex. – Willing to comply with protocol instructions, including allowing all study assessments. – Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area >12 cm2 to ≤ 36 cm2 – Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence. – Arterial supply adequacy confirmed – Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone. – Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months). – Acceptable state of health and nutrition Exclusion Criteria:

  • History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B. – Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication. – Therapy with another investigational agent within thirty (30) days of Screening, or during the study. – A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic). – Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit. – Refusal of or inability to tolerate compression therapy. – Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit. – History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers). – Any prior exposure to HP802-247 or its vehicle.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Healthpoint
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Herbert B Slade, MD, Study Chair, Healthpoint
    • Tommy Lee, MSHS, Study Director, Healthpoint
    • Robert Kirsner, MD, Principal Investigator, University of Miami
    • William Marston, MD, Principal Investigator, University of North Carolina

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.